Search results
Results from the WOW.Com Content Network
UpToDate, Inc. is a company in the Wolters Kluwer Health division of Wolters Kluwer, the main product of which is the eponymous UpToDate, a software system that is a point-of-care medical resource. The UpToDate system is an evidence-based clinical resource. It includes a collection of medical and patient information, access to Lexicomp drug ...
Optune was approved by the FDA for newly diagnosed glioblastoma on Oct. 5, 2015, [31] as a result of randomized phase 3 trial results that reported a 3-month advantage in overall survival and progression-free survival when added to chemotherapy with temozolomide. [23] [24] In the US, Medicare covers treatment, as of February 2020. [32]
The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite. [7] Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody. [5][8] Tafasitamab was approved for medical use in the United States in July 2020, [7][8][9] and in the ...
Calaspargase pegol is an engineered protein consisting of the E. coli -derived enzyme L-asparaginase II conjugated with succinimidyl carbonate monomethoxypolyethylene glycol (pegol). [6] The L-asparaginase portion hydrolyzes L-asparagine to L-aspartic acid depriving the tumor cell of the L-asparagine it needs for survival. [6]
Voxelotor. Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. [1][3][4][5][6] Voxelotor is the first hemoglobin oxygen-affinity modulator. [7] Voxelotor has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell ...
The trial measured the average number of cluster headaches per week for three weeks and compared the average changes from baseline in the galcanezumab and placebo groups. [6] During the three-week period, participants taking galcanezumab experienced 8.7 fewer weekly cluster headache attacks than they did at baseline, compared to 5.2 fewer ...
Burton Rose was a clinical professor of medicine at Harvard University. [3] He also held positions at the University of Massachusetts Medical School, Brigham and Women's Hospital, and Beth Israel Deaconess Medical Center. [2] He was the author of Clinical Physiology of Acid-Base and Electrolyte Disorders and Pathophysiology of Renal Disease ...
In 1931, the first commercially available human chorionic gonadotropin (hCG) was launched, [2] which marked the first emergence of female fertility agents. Subsequently, clomiphene citrate was discovered in 1951, which was then approved by the Food and Drug Administration (FDA) in 1967. [3]